Marius C. Wick

Longitudinal analysis of citrullinated protein/peptide antibodies (anti-CP) during 5 year follow up in early rheumatoid arthritis: anti-CP status predicts worse disease activity and greater radiological progression

Johan Rönnelid, Marius C. Wick, Jon Lampa et al. · Annals of the Rheumatic Diseases · 2005 · 340 citations · Full text

Antibodies against citrullinated vimentin in rheumatoid arthritis: Higher sensitivity and extended prognostic value concerning future radiographic progression as compared with antibodies against cyclic citrullinated peptides

Linda Mathsson, Mohammed Mullazehi, Marius C. Wick et al. · Arthritis & Rheumatism · 2007 · 206 citations

Increased Fracture Risk in Patients with Rheumatic Disorders and Other Inflammatory Diseases — A Case-Control Study with 53,108 Patients with Fracture: Table 1.

Rüdiger J Weiss, Marius C. Wick, Paul W. Ackermann et al. · The Journal of Rheumatology · 2010 · 129 citations · Full text

Adalimumab (Humira®) restores clinical response in patients with secondary loss of efficacy from infliximab (Remicade®) or etanercept (Enbrel®): results from the STURE registry at Karolinska University Hospital

Marius C. Wick, Sofia Ernestam, Staffan Lindblad et al. · Scandinavian Journal of Rheumatology · 2005 · 119 citations

Decrease of RA-related orthopaedic surgery of the upper limbs between 1998 and 2004: data from 54 579 Swedish RA inpatients

R. J. Weiss, Anna Ehlin, Scott Montgomery et al. · Lara D. Veeken · 2007 · 86 citations · Full text